Kite Pharma (KITE) Posts Q1 Loss of 20c/Share

Kite Pharma (NASDAQ: KITE) reported Q1 EPS of ($0.20), $0.32 worse than the analyst estimate of $0.12. Revenue for the quarter came in at $2.9 million versus the consensus estimate of $19.7 million.

For earnings history and earnings-related data on Kite Pharma (KITE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c